Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria - Subjects who meet ALL of the following criteria are eligible for the study:~1. Participant is 18 to 55 years of age~2. Participant who has a smart phone and is willing and able to install and use the eDiary.~3. Participant has an understanding of the study and its procedures, agrees to its provisions, and voluntarily gives written informed consent prior to any study-related procedures.~4. Participant is generally healthy as determined by the Investigator~5. Participant has a Body Mass Index (BMI) of 18.0-30.0 kg/m2~6. If subject is of childbearing potential:~   1. Participant has practiced an adequate method of contraception during the 30 days before screening (Visit 0).~  2. Participant has a negative serum or urine pregnancy test at screening (Visit 0) or Visit 1, respectively.~  3. Participant agrees to employ adequate birth control measures up to Day 106 (Visit 5).~Inclusion Criteria for Booster Phase - Subjects who meet ALL of the following criteria are eligible for the Booster phase:~* B1. Participant has received complete VLA2001 primary immunization (two vaccinations according to the protocol)~* B2. Participant who has a smart phone and is willing and able to install and use the e-Diary.~* B3. Participant has an understanding of the study and its procedures, agrees to its provisions, and voluntarily gives written informed consent prior to any study-related procedures.~* B4. Participant is generally healthy as determined by the Investigator's clinical judgement~* B5. If a participant is of childbearing potential:~  1. Participant has a negative urine pregnancy test at Visit 7 prior to booster vaccination.~ 2. Participant agrees to employ adequate birth control measures up to 3 months after the Booster vaccination.~Exclusion criteria - Participants who meet ANY of the following criteria are NOT eligible for this study:~1. Clinically significant infection or other acute illness, including fever ≥ 38°C within 24 hours prior to the planned study vaccination.~2. History of laboratory-confirmed SARS-CoV-2 infection.~3. Participant had close contact to persons with confirmed SARS-CoV-2 infection within 30 days prior to screening (Visit 0).~4. Participant has participated in a clinical study involving an investigational SARS-CoV-2 vaccine.~5. Participant has an acute or recent infection not due to SARS-CoV-2~6. Participant has a history of SARS-CoV-1 or MERS infection (self-reported)~7. Participant tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).~8. Participant has received any vaccine within 30 days prior Visit 1 other than the study intervention, with the exception of the seasonal influenza vaccination.~9. Participant has abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator.~10. Participants with either medical history of or present acute or progressive, unstable or uncontrolled clinical conditions that pose a risk for participation or completion of the study, based on Investigator's clinical judgement.~11. Participants with underlying diseases with a high risk of developing severe COVID-19 symptoms if infected~12. Participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the subject may be enrolled. A history of hematologic malignancy is a permanent exclusion. Participants with a history of skin cancer must not be vaccinated at the previous tumour site.~13. Participant has a known or suspected defect of the immune system, such as Participants with congenital or acquired immune deficiency~14. Participant received immuno-suppressive therapy within 4 weeks prior to Visit 1 or receipt of immunosuppressive therapy is expected during the study.~15. Participant has a history of any vaccine related contraindicating event~16. Participant presents with clinical conditions representing a contraindication to intramuscular vaccination and blood draws.~17. Participant is pregnant, has plans to become pregnant up to Day 106 of the study or lactating at the time of enrolment.~18. Participant has donated blood, blood fractions or plasma within 4 weeks prior to Visit 1 or received blood-derived products (e.g. plasma) within 12 weeks prior to Visit 1 in this study or plans to donate blood or use blood products during the study.~19. Participant with clinically significant bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder) or prior history of significant bleeding or bruising following IM injections or venepuncture.~20. Participant has a rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating.~21. Participant has a known or suspected problem with alcohol or drug abuse as determined by the Investigator.~22. Participant has any condition that, in the opinion of the Investigator, may compromise the Participant's well-being, might interfere with evaluation of study endpoints, or would limit the Participant's ability to complete the study.~23. Participant is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).~24. Participant has participated in another clinical study involving an investigational medicinal product (IMP) or device within 4 weeks prior to Visit 0 (screening) or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study.~25. Participant is a member of the team conducting the study or in a dependent relationship with one of the study team members.~Exclusion Criteria for Booster Phase - Participants who meet ANY of the following criteria are NOT eligible for Booster phase:~* B1. Clinically significant infection or other acute illness, including fever ≥ 38°C within 48 hours prior to the planned Booster vaccination.~* B2. Participant has an acute or recent infection not due to SARS-CoV-2 and is not symptom-free in the week prior to the Booster vaccination (Visit 7).~* B3. Participant has received any vaccine within 30 days prior Visit 7, with the exception of the seasonal influenza vaccination. Participants will be encouraged to receive this vaccination at least 7 days after their Booster vaccine.~* B4. Participant has abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) that is considered clinically relevant by the Investigator.~* B5. Participant has received immuno-suppressive therapy within 4 weeks prior to Visit 7 or is expected to receive immunosuppressive therapy during the study. Immunosuppressive therapy is defined as administration of chronic (longer than 2 weeks) prednisone or equivalent ≥ 0.05 mg/kg/day within 4 weeks prior to Visit 7 (topical and inhaled steroids are allowed), radiation therapy or immunosuppressive cytotoxic drugs or monoclonal antibodies in the previous 3 years.~* B6. Participant has clinical conditions representing a contraindication to intramuscular vaccination and blood draws.~* B7. Participant is pregnant (positive urine pregnancy test at Visit 7, respectively), has plans to become pregnant up to 3 months after the Booster vaccination.~* B8. Participant has a rash, dermatological condition that would, in the opinion of the Investigator, interfere with injection site reaction rating.~* B9. Participant has a known or suspected problem with alcohol or drug abuse as determined by the Investigator.~* B10. Participant has any condition that, in the opinion of the Investigator, may compromise the Participant's well-being, might interfere with evaluation of study endpoints, or would limit the Participant's ability to complete the study.~* B11. Participant is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).~* B12. Participant has participated in another clinical study involving an investigational medicinal product (IMP) or device within 4 weeks prior to Visit 7 or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Low Dose: VLA2001 (Type: EXPERIMENTAL): None
- Medium Dose: VLA2001 (Type: EXPERIMENTAL): None
- High Dose: VLA2001 (Type: EXPERIMENTAL): None
- Booster: High Dose: VLA2001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete